Biomarkers are crucial signposts in understanding and combating disease, guiding researchers and clinicians. Mass cytometry has revolutionized our ability to discover and validate these biological indicators, ushering in a new era of precision medicine.
The Dawn of Mass Cytometry in Biomarker Discovery
The groundbreaking work of Bendall et al., published in Science in 2011 (cited over 2000 times), marked a pivotal moment in the field of biomarker discovery. Their study, “Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum,” demonstrated the unprecedented power of mass cytometry to analyze multiple parameters at the single-cell level simultaneously. They specifically used mass cytometry, not flow cytometry. This study was, in fact, one of the pioneering works that introduced mass cytometry (CyTOF – Cytometry by Time of Flight) as a powerful tool for high-dimensional single-cell analysis.
Restricted content
You must be logged in and have a valid subscription to see this content. Please visit our subscription page for more info. If you are already a VIP member, be sure you are logged in with the same email address you made your purchase.
